It's only a pill, but its impact could be a life-changing: PrEP is a daily medication that significantly reduces the risk of contracting HIV from a positive sexual partner. The FDA approved PrEP in July 2012. Legacy began its PrEP program a year later to spread the word about this revolutionary new way to prevent HIV and AIDS.
The number of new annual HIV infections in Houston has remained relatively steady over the past five years. Legacy believes that 1200-1300 new diagnoses each year is far too many and has launched an ambitious effort to cut that number in half by 2021, thanks to a new grant from AIDS United and its Southern REACH initiative. The END (Ending New Diagnoses) HIV/AIDS Houston Project will provide a plan for the City of Houston that will outline specific actions to be taken, identify funding resources, and set a road map for how the city can reduce new HIV diagnoses.
